MAPT and Parkinson disease: In summary therefore, we present some new methods of assessing α-syn levels in CSF from patients with parkinsonian disorders, and show that those assays based on the detection of phosphorylated oligomeric forms of α-syn may have utility in differentiating patients with MSA from other parkinsonian disorders in which the underlying pathology is also α-syn based (i.e. PD and DLB) or is tau-based (i.e. PSP).